Vor Biopharma Inc
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML… Read more
Vor Biopharma Inc (VOR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.024x
Based on the latest financial reports, Vor Biopharma Inc (VOR) has a cash flow conversion efficiency ratio of 0.024x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-53.66 Million) by net assets ($-2.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vor Biopharma Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Vor Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vor Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vor Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mitsubishi Paper Mills Limited
F:MPX
|
N/A |
|
Valens
NYSE:VLN
|
-0.043x |
|
Mobase Electronics Co.Ltd
KQ:012860
|
0.082x |
|
IMMOB. BELG. SA
F:R5L
|
N/A |
|
PT Harum Energy Tbk
F:44H
|
0.010x |
|
New Power Plasma Co.Ltd
KQ:144960
|
0.051x |
|
Shanthi Gears Limited
NSE:SHANTIGEAR
|
0.118x |
|
Integrated Wind Solutions AS
OL:IWS
|
0.104x |
Annual Cash Flow Conversion Efficiency for Vor Biopharma Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Vor Biopharma Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $96.66 Million | $-99.66 Million | -1.031x | -54.94% |
| 2023-12-31 | $150.72 Million | $-100.29 Million | -0.665x | -95.85% |
| 2022-12-31 | $250.61 Million | $-85.14 Million | -0.340x | -6.26% |
| 2021-12-31 | $216.26 Million | $-69.14 Million | -0.320x | +57.47% |
| 2020-12-31 | $48.27 Million | $-36.29 Million | -0.752x | +41.71% |
| 2019-12-31 | $7.64 Million | $-9.86 Million | -1.290x | -428.03% |
| 2018-12-31 | $-6.77 Million | $-2.66 Million | 0.393x | -- |